Background. Acute flaccid myelitis (AFM) is an acute flaccid paralysis syndrome with spinal motor neuron involvement of unknown etiology. We investigated the characteristics and prognostic factors of AFM clusters coincident with an enterovirus D68 (EV-D68) outbreak in Japan during autumn 2015.
In response to AFP reports received by NIID, provisional AFP surveillance commenced 21 October 2015 [8] . All AFP cases admitted between 1 August 2015 and 31 December 2015 with new-onset neurological symptoms lasting >24 hours, but excluding those with definitive etiologies (vascular, tumor, and trauma), were included in the present study. As acute cranial nerve dysfunction with brainstem lesions (ACB) is considered one of the neurological manifestations of this syndrome and reported alongside AFM in a previous US report [4] , a preliminary survey by the Japanese Society of Child Neurology included ACB cases. Following this national AFP survey, we undertook the AFM collaborative study by requesting medical data from participating clinicians. Acute flaccid myelitis was defined per criteria adopted [10] . Confirmed AFM was defined by onset of acute focal limb weakness and evidence of spinal cord lesion with predominant gray matter involvement on magnetic resonance imaging (MRI). Probable AFM was defined by acute focal limb weakness and a CSF profile showing pleocytosis with leukocyte count >5 cells/µL. Acute disseminated encephalomyelitis (ADEM), acute transverse myelitis, neuromyelitis optica spectrum disorders (NMOSDs), and Guillain-Barré syndrome (GBS) were defined per the established criteria [11] [12] [13] [14] . All MRI and neurophysiological data were sent to a panel of specialists for review. Oral or written consent was obtained from all patients or guardians, and ethical approval for this study was granted by the Ethics Committee of NIID, Japan (number 655).
Procedures
Detailed anonymized medical data were obtained from clinicians. Motor function was assessed by manual muscle strength test (MMT) and graded per the Medical Research Council scale [15] . Overall MMT score was calculated from the sums of average muscle strengths in each paralyzed extremity divided by the number of affected limbs. Motor improvement was classified using a 4-level system: complete (grade 5 on MMT score); good (2 or more grades of MMT score recovery or grade 4 on MMT score); fair (slight improvement); and poor (no improvement). All patients with neurological sequela were reevaluated after 6 months or more. Neuroimaging data were reviewed independently by a radiologist (H. M.) and a child neurologist (A. O.). Neurophysiological reports were reviewed by 2 child neurologists (H. T. and S. Y.). Discussions were held between core members (P. F. C., R. K., H. M., A. O., H. T., S. Y., K. T. T.) in uncertain cases. Clinical specimens such as serum, CSF, throat or nasopharyngeal swabs, stool, and urine were obtained for available cases. Specimens were tested by the prefectural and municipal public health institutes (PMPHIs) or NIID. At NIID, enterovirus was detected by real-time reverse-transcription polymerase chain reaction (RT-PCR) using 2 EV-D68-specific assays [3, 16] , and 1 pan-enterovirus assay [17] . To confirm the accuracy of real-time RT-PCR identification, some of the PCR products were sequenced and identified by the partial VP1 sequence. Two EV-D68-positive cases were identified independently at 2 PMPHIs by sensitive, seminested RT-PCR using the consensus degenerate hybrid oligonucleotide primers [18] and partial VP1 sequencing.
Analysis of Epidemiological and Clinical Data
Associations between the AFM epidemic curve and nationwide trends in EV-D68-positive and other pathogen-positive cases from the epidemiological data of Infectious Agents Surveillance Report (IASR) were examined using the Pearson correlation. The weekly number of EV-D68-positive cases were obtained from the IASR dataset under the National Pathogen Surveillance System of Japan. The EV-D68-positive cases are voluntarily reported from the PMPHIs because EV-D68 infection is not classified as a notifiable disease [19, 20] . We used 
RESULTS
During the study period, 115 AFP cases from 89 hospitals were reported nationwide from event-based surveillance initiated under special provision of the Infectious Disease Prevention Law, capturing almost all of the AFP cases. Of the 101 possible cases enrolled in the AFM collaborative study, 59 satisfied the definition of AFM (58 confirmed and 1 probable case) (Figure 1 ), while no AFM cases satisfied the diagnostic criteria for ADEM, NMOSDs, or GBS, and only 1 AFM case fulfilled the criteria for acute transverse myelitis.
Temporal Correlation of AFM With EV-D68 Detection Rate
The AFM epidemic curve for 2015 followed a trend like that of weekly reported EV-D68-positive cases ( Figure 2 ). Pearson correlation analysis revealed a strong association with EV-D68 trend (r = 0.91), an association not observed for other Positive (31) Positive (23) Negative ( Table 4) . Enterovirus A71 and poliovirus, important causative agents of AFP, were not detected during this period.
Pathogen Detection
This strong temporal correlation prompted us to test for EV-D68 in available biological samples of AFM cases at NIID. Among 20 cases tested, 7 (35%) were EV-D68 positive: 3 from respiratory, 2 from stool, 1 from CSF, and 1 from nasopharyngeal, serum, and tracheal aspiration samples (a pediatric case with preceding steroid usage) [21] . Remarkably, EV-D68 was detected in a CSF sample collected 1 day after the AFM onset from an adult AFM case (Table 1 , case 54) by EV-D68-specific real-time RT-PCR [22] . Two additional AFM cases with EV-D68-positive nasopharyngeal samples were identified at PMPHIs, for a total of 9 EV-D68-positive cases (15%) ( Table 2) . We also tested for EV-D68 in non-AFM AFP patients and identified 2 additional cases, an ACB patient with positive serum and a cerebellar ataxia patient with a positive nasopharyngeal sample. Most EV-D68-positive samples were collected within 1 week after AFM onset; however, EV-D68 was detected in 1 case from several samples obtained at different times. Table 3 shows the demographic features of the AFM patient group. Median age was 4.4 years (interquartile range [IQR], 2.6-7.7 years). Most cases were children, but 4 adults (7%) satisfied the inclusion criteria ( Figure 3A) . No known comorbidities before symptom onset were noted in 41 patients (69%), whereas 10 (17%) had asthma. Before neurological symptom onset, 52 patients (88%) had fever and experienced a prodromal illness with respiratory (75%) or gastrointestinal (19%) symptoms. Fever occurred 3.5 days (IQR, 1.0-5.3) before neurological symptoms and lasted about 4 days, with a peak body temperature of 38.5°C. Most cases (78%) exhibited rapid onset with neurological symptoms progressed rapidly within 48 hours. All patients Table 2 ). In addition, 40 patients (68%) developed muscle atrophy in the paralyzed limbs during the clinical course. Clinical features of patients who tested positive for EV-D68 are summarized in Table 1 .
Clinical Characteristics of AFM

Neuroradiological Features
All 59 patients underwent at least 1 spinal MRI, and 56 patients underwent brain MRI. Abstracted data are summarized in Table 3 and Figure 3B , and representative images are shown in Figure 4 . Consistent with previous reports, all confirmed AFM patients had longitudinal cord lesions spanning a median of 20 vertebral levels (length determinable in 47 patients). Brainstem lesions were observed in 25 (42%) cases. Gadolinium was administered in 39 patients, revealing parenchymal enhancement in 3 cases (5%), ventral nerve root enhancement in 9 (15%), and cauda equina enhancement in 30 (51%). Predominant spinal gray matter involvement could not be determined in the only probable AFM patient (Table 1) , who exhibited enhancement in cauda equina and both thoracic and lumbar ventral roots, clinically diagnosed as radiculoneuritis.
Neurophysiological Features
Neurophysiological investigation results are summarized in Table 3 . Most studies were conducted within 2 weeks of neurological onset. Abnormal motor conduction was detected in 42 of 51 patients (82%), while 30 of 41 (73%) exhibited abnormal F-waves (Supplementary Table 5 ).
Cerebrospinal Fluid Features
Eighty-nine CSF specimens were obtained from 59 patients. Pleocytosis was present in 50 patients (85%), and CSF protein level was elevated in 27 (46%) at initial lumbar puncture. When all CSF specimens were considered, earlier lumbar puncture after neurological symptom onset yielded higher leukocyte count ( Figure 5 ). In the 42 samples tested 0-5 days after onset, 40 (95%) showed pleocytosis.
Serum Immunology
None of the patients tested positive for anti-aquaporin 4 (AQP4) antibody or antimyelin oligodendrocyte glycoprotein (MOG) antibody. Anti-AQP4 antibody is a major pathogenic antibody detectable and is included as a diagnostic criteria in NMOSDs [13] , while anti-MOG antibody has been associated with demyelinating disease of the central nervous system, including multiple sclerosis, NMOSDs, and ADEM [23] . were defined as having good outcome, and those with fair or poor improvement as having poor outcome. Most patients treated with IVIG or mPSL, even with early initiation after neurological onset, showed poor outcome. Cases with pretreatment MMT scores >3 (P = .013) and negative for EV-D68 (P = .048) showed good motor prognosis (Table 4) . However, multiple regression analysis identified normal F-wave persistence as the only significant independent factor for good prognosis (P = .010). Other neurological symptoms usually had good outcome, with only 1 patient exhibiting residual facial paralysis, 2 paresthesia, and 3 neurogenic bladder at follow-up (Supplementary Table 2 ).
DISCUSSION
Although EV-D68 infections are mainly associated with respiratory illness, previous North American reports from 2014 suggested a strong epidemiological association with AFM [2, 4, 6] . In the present study, we detected EV-D68 in 9 AFM patients, including in the CSF (1/9) and blood (1/9) specimens of patients. Additional supporting evidence for a link between EV-D68 infection and AFM included a strong temporal correlation, with both incidences peaking within a 2-to 3-week period. Furthermore, no such associations were observed for other viruses. This sudden increase in AFM cases during an EV-D68 outbreak and a second such occurrence, separated by 1 year and in a distant geographical area from the first, strongly suggests that EV-D68 is a major causative agent for AFM. Core symptoms of AFM had been described as motor dominant, consistent with involvement of anterior horn neurons [1] . Although limb paralysis varied in type and severity, most cases showed extensive longitudinal spinal involvement (median of 20 spinal segments), and CSF pleocytosis (95% in samples taken within 0-5 days of onset), further confirming AFM as a defined clinical syndrome, although these traits were more pronounced than in previous US reports [2] [3] [4] . Alternatively, no AFM case fulfilled the diagnostic criteria for ADEM or NMOSDs with negative test results for anti-AQP4 and anti-MOG antibodies, indicating largely nonoverlapping clinical features. On the other hand, brainstem, and spinal root lesions were observed in 42% and 15% of radiographically investigated cases, respectively. Neurophysiological studies also confirmed peripheral nerve involvement in >80% of tested cases. Further, EV-D68 was detected in 1 ACB case without apparent spinal lesion involvement (Table 1 , case 64), and 1 with an interquartile range of 2.6-7.7 y. A total of 35 male and 24 female patients, including 4 adult patients, was reported in this period. B, Extensive longitudinal lesions were observed in most of the cases. *Unknown due to incomplete data (total spinal magnetic resonance imaging not done) or poor radiographic images.
clinically diagnosed radiculoneuritis (Table 1 , case 42), suggesting that neurological complications of EV-D68 infection can extend to or specifically target brainstem and peripheral nerves with myelitis as the predominant feature.
While previous reports suggested predominant neurological manifestations, not all EV-D68 infections have been linked to AFM [26] . Indeed, Japanese IASR data during the 2015 outbreak detected EV-D68 mainly from patients with respiratory symptoms [27] . Like poliovirus and hand, foot, and mouth disease (HFMD), only a small fraction EV-D68 infection cases manifested neurological symptoms [26] . Apparent polio cases are identified among <1% of the infected individuals and the case-severity rate among HFMD cases was reported to be 1.1% [28, 29] .
Only 3 cases, 1 adult with AFM [22] , 1 adult with ACB, and a pediatric AFM patient with early steroid usage [21] , had EV-D68 in blood or CSF specimens, suggesting that host susceptibility factors increase the risk of neurological manifestations. Administration of steroids for asthma in the pediatric patient 5 days before neurological onset may have induced transient immunosuppression and persistent viremia. Differences in the immune responses in adults may have resulted in prolonged viremia and CSF presence, or increased viral load. Among paralytic cases due to poliomyelitis, the case-severity rate in adults has been reported to be higher than in infants [28] . Clinical features also differed between adult and pediatric cases in that adults more frequently exhibited subacute onset (75% with neurological symptoms progressing in >72 hours) and extramotor symptoms (75% with cranial neuropathy; 50% with neurogenic bladder, focal paresthesia, and altered mental status). Considering the poorer prognosis of EV-D68-positive cases, it is plausible that the balance between host responses to EV-D68 and viral clearance contributes to disease susceptibility.
Acute flaccid myelitis is a new clinical entity originally defined during a 2014 EV-D68 outbreak [30] , but the pathomechanisms are still uncertain because many cases are without detectable EV-D68 infection. Clinical and radiographic patterns appear like those of poliovirus, enterovirus A71, and West Nile virus, suggesting a common pathophysiology [31] [32] [33] . However, active surveillance in the United States during 2015-2016 failed to consistently detect EV-D68 in sporadic AFM cases. Inability to detect EV-D68 in CSF makes direct neuroinvasion as the sole infection route unlikely. Selective localization to spinal motor neurons, which typically occurs during the acute stage of an infection, and detection of antiganglioside antibodies (median of 2.5 sampling days from onset) as seen in GBS point to an immune-mediated process following a parainfectious profile.
Antiganglioside antibodies targeted gangliosides in the peripheral nervous system causing immune-mediated polyradiculoneuropathy, including GBS, through molecular mimicry, usually after an infectious event [34] . It is also possible that several mechanisms, ranging from infectious to parainfectious, contribute to the disease spectrum of AFM.
To our knowledge, none of the earlier reports on AFM investigated prognostic factors. In the present study, severe pretreatment limb weakness (MMT score ≤3) was associated with poor outcome, and immunomodulation therapy failed to ameliorate neurological consequences irrespective of therapeutic agent or timing. This treatment failure could be caused by the rapid progression of neurological symptoms. Considering these poor neurological outcomes, vaccine development might offer the best option for disease control if further evidence implicates EV-D68 as a critical AFM-causing agent [35] . Preserved F-waves and other electrophysiological metrics are good predictors of clinical prognosis. Successful restoration of upper Statistically significance (P < .05). c All 9 EV-D68-positive cases had poor outcome, whereas 34% of EV-D68-negative cases had good outcome. Thus, relative risk by univariate analysis and odds ratio by multivariate analysis could not be performed.
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• CID 2018:66 (1 March) • Chong et al limb function was reported in AFP patients following nerve and muscle transfer [36, 37] ; therefore, these procedures may be therapeutic options for patients with predicted poor outcome.
There are some limitations to our study, including a lack of recent comparative data. There had been no routine surveillance for AFP in Japan since the last poliomyelitis case owing to wild poliovirus in 1980 [38] , and the actual numbers of AFP/ AFM cases and associated infectious agents were not officially monitored before the introduction of provisional AFP surveillance in October 2015. Second, infectious agent surveillance protocols for AFP/AFM, including timely sample collection, and laboratory diagnosis systems for EV-D68 and other possible agents have not been established and standardized. Third, the possibility of other pathogens causing AFM via similar pathomechanisms cannot be excluded as we only focused on EV-D68 detection because of the limited sample volume. Indeed, during the 2014 US outbreak, enterovirus C105, influenza virus, and other pathogens were detected in patients with AFM [2, 3, 5, 7, 39] .
Our study clarifies the clinical characteristics of AFM and expands the spectrum of neurological involvement observed during an EV-D68 outbreak. Clusters of AFM cases were temporally correlated with reported EV-D68 infections, and detection of EV-D68 in CSF and serum specimens provided further evidence that EV-D68 may be one of the major causative agents for AFM. However, the relatively low EV-D68 detection rate and the many sporadic cases without detectable EV-D68 infection suggest that factors such as host susceptibility predispose to AFM. With no effective treatment identified in the acute stage, studies are required to elucidate the pathophysiology and pathomechanisms of AFM and to develop both preventive measures and novel therapeutic interventions.
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